SCHEMBL6144495

SCHEMBL6144495

CCCCOC(C(=O)Oc1ccc(C(=O)O)cc1)c1ccc2c(c1)C(C)(C)CCC2(C)C

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CYP26A1 O43174 5/20 0.60
CYP3A4 P08684 4/20 0.60
CYP26B1 Q9NR63 3/20 0.60
RXRA P19793 10/20 0.57
HNF4A P41235 1/20 0.57
RXRB P28702 7/20 0.56
RXRG P48443 5/20 0.52
RARB P10826 7/20 0.52
RARG P13631 7/20 0.52
RARA P10276 5/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6144036 1.00 CYP26A1 (0.60) CYP26A1CYP3A4CYP26B1RXRAHNF4A
SCHEMBL6147485 1.00 CYP26A1 (0.60) CYP26A1CYP3A4CYP26B1RXRAHNF4A
SCHEMBL6146814 0.96 CYP26A1 (0.60) CYP26A1CYP3A4CYP26B1RXRAHNF4A
SCHEMBL6147351 0.91 CYP26A1 (0.62) CYP26A1CYP3A4CYP26B1RXRAHNF4A
SCHEMBL6143991 0.87 CYP3A4 (0.46) CYP26A1CYP3A4CYP26B1RXRAHNF4A
SCHEMBL6147153 0.87 CYP3A4 (0.46) CYP26A1CYP3A4CYP26B1RXRAHNF4A
SCHEMBL6147238 0.85 RARB (0.63) CYP26A1CYP3A4CYP26B1RXRARXRB
SCHEMBL6144635 0.84 RXRA (0.52) CYP26A1CYP3A4CYP26B1RXRAHNF4A
SCHEMBL6143581 0.84 CYP26A1 (0.56) CYP26A1CYP3A4CYP26B1RXRAHNF4A
SCHEMBL6143656 0.84 CYP26A1 (0.54) CYP26A1CYP3A4CYP26B1RXRAHNF4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1280757-B1 NEW GAMMA SELECTIVE RETINOIDS HOFFMANN LA ROCHE (CH) 2005-08-17 EP claimed
EP-1280757-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2003-02-05 EP claimed
US-20020026060-A1 RAR selective retinoid agonists F.HOFFMANN-LA ROCHE AG (CH) 2002-02-28 US claimed
WO-2001083438-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 WO claimed
EP-1280757-B1 NEW GAMMA SELECTIVE RETINOIDS HOFFMANN LA ROCHE (CH) 2005-08-17 EP disclosed
US-6603012-B2 RAR selective retinoid agonists HOFFMANN-LA ROCHE INC. 2003-08-05 US disclosed
EP-1280757-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2003-02-05 EP disclosed
US-20020026060-A1 RAR selective retinoid agonists F.HOFFMANN-LA ROCHE AG (CH) 2002-02-28 US disclosed
WO-2001083438-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020026060-A1 RAR selective retinoid agonists RARA, RARG, RARB CYP26A1 474/4885CYP3A4 2129/4885CYP26B1 923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.